A new generation of drug delivery technology is emerging, with new refillable, absorbable, and dissolvable drug delivery systems making their way through clinical trials and into the market. Large pharmaceutical companies, biotech firms, and device startups alike are all developing innovative alternatives to intravitreal injection.

These systems are important for improving compliance and, as a result, patient outcomes. The ability to extend treatment duration also alleviates some of the patient and physician burden that comes with regular injections.

To explore the latest advances in the ocular drug delivery space and their impact on patients and clinics, OIS brought together an A team of medical, venture capital, and industry experts.

Listen to this podcast to hear our panel discuss: 

• Do longer-lasting therapies, injectables, and resorbables represent a new bar for existing technologies?
• What’s in development at Bausch + Lomb, Aerie Pharmaceuticals, and Allergan/Abbvie?
• How will these new delivery systems change the dynamics in the clinic?
• What should companies starting to commercialize keep in mind to ensure success?